Cost-effectiveness of initiating dialysis early: A randomized controlled trial

American Journal of Kidney Diseases

Volumn 57, Issue 5, 2011, Pages 707-715

  Harris, Anthony ^a   Cooper, Bruce A ^b   Li, Jing Jing ^a   Bulfone, Liliana ^a,c   Branley, Pauline ^d   Collins, John F ^e   Craig, Jonathan C ^b   Fraenkel, Margaret B ^f   Johnson, David W ^g   Kesselhut, Joan ^b   Luxton, Grant ^h   Pilmore, Andrew ^e   Rosevear, Martin ⁱ   Tiller, David J ^j   Pollock, Carol A ^b   Harris, David C ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f AUSTIN HOSPITAL   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ Outome Management Services   (New Zealand)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Chronic kidney disease; cost; cost effectiveness; dialysis; economic evaluation; quality of life; randomized

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHATE;

ADULT; AGED; ARTICLE; AUSTRALIA; BODY MASS; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DIASTOLIC BLOOD PRESSURE; EARLY INTERVENTION; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HOSPITALIZATION COST; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEW ZEALAND; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PSYCHOLOGICAL WELL BEING; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFLUX NEPHROPATHY; REIMBURSEMENT; RENOVASCULAR DISEASE; SCORING SYSTEM; SHORT FORM 36; SMOKING; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; TREATMENT DURATION; TREATMENT PLANNING;

AGED; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954525737     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.12.018     Document Type: Article

References (24)

1. V. Bonomini, A. Vangelista, and S. Stefoni Early dialysis in renal substitutive programs Kidney Int Suppl 8 1978 S112 S116
2. P. Jungers, J. Zingraff, G. Albouze, P. Chauveau, B. Page, and T. Hannedouche Late referral to maintenance dialysis: detrimental consequences Nephrol Dial Transplant 8 1993 1089 1093 (Pubitemid 23322623)
3. J. Tattersall, R. Greenwood, and K. Farrington Urea kinetics and when to commence dialysis Am J Nephrol 15 1995 283 289
4. B.A. Cooper, P. Branley, and L. Bulfone The Initiating Dialysis Early and Late (IDEAL) Study: study rationale and design Perit Dial Int 24 2004 176 181 (Pubitemid 38515082)
5. B.A. Cooper, P. Branley, and L. Bulfone A randomized, controlled trial of early versus late initiation of dialysis N Engl J Med 363 2010 609 619
6. Organisation for Economic Co-operation and Development (OECD) OECD StatExtracts http://stats.oecd.org/Index.aspx?datasetcode=SNA-TABLE4 Accessed December 9, 2010
7. G. Hawthorne, J. Richardson, and R. Osborne The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life Qual Life Res 8 1999 209 224 (Pubitemid 29367290)
8. J. Richardson, N. Day, S. Peacock, and A. Iezzi Measurement of the quality of life for economic evaluation and the Assessment of Quality of Life (AQoL) Mark 2 Instrument Aust Econ Rev 37 1 2004 62 88 (Pubitemid 38536560)
9. R. Chua, A.M. Keogh, K. Byth, and A. O'Loughlin Comparison and validation of three measures of quality of life in patients with pulmonary hypertension Int Med J 36 2006 705 710 (Pubitemid 44563431)
10. J. Ware, and C. Sherbourne The MOS 36-Item Short-Form Health Survey (SF-36) Med Care 30 1992 473 483
11. Australian Bureau of Statistics. 1995 National Health SurveySF-36 Population Norms. ABS Catalogue No. 43990; Canberra 1997.
12. H. Bang, and A.A. Tsiatis Estimating medical costs with censored data Biometrika 87 2000 329 343
13. B. Efron, and R. Tibshirani An Introduction to the Bootstrap 1993 Chapman & Hall New York, NY
14. World Health Organisation Cost effectiveness thresholds http://wwwwhoint/choice/costs/CER-thresholds/en/printhtml Accessed April 22, 2010
15. A.R. Willan Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data Control Clin Trials 22 2001 228 237 (Pubitemid 32522469)
16. L. Scalone, F. Borghetti, and G. Brunori Cost-benefit analysis of supplemented very low-protein diet versus dialysis in elderly CKD5 patients Nephrol Dial Transplant 25 2010 907 913
17. K. Baboolal, P. McEwan, S. Sondhi, P. Spiewanowski, J. Wechowski, and K. Wilson The cost of renal dialysis in a UK settinga multicentre study Nephrol Dial Transplant 23 2008 1982 1989 (Pubitemid 351768145)
18. N. Neil, S. Guest, and L. Wong The financial implications for Medicare of greater use of peritoneal dialysis Clin Ther 31 2009 880 888
19. J.L. Zelmer The economic burden of end-stage renal disease in Canada Kidney Int 9 2007 1045 1047
20. C.P. Lee, G.M. Chertow, and S.A. Zenios An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard Value Health 12 2009 80 87
21. W.C. Winkelmayer, M.C. Weinstein, M.A. Mittleman, R.J. Glynn, and J.S. Pliskin Health economic evaluations: the special case of end-stage renal disease treatment Med Decis Making 22 2002 417 430
22. National Institute for Health and Clinical Excellence Appraising life-extending, end of life treatments http://wwwniceorguk/media/88A/F2/ SupplementaryAdviceTACEoLpdf 2009 Accessed December 2, 2010.
23. A.H. Harris, S.R. Hill, G. Chin, J.J. Li, and E. Walkom The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004 Med Decis Making 28 2008 713 722
24. A.W. Wu, N.E. Fink, and J.V. Marsh-Manzi Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures J Am Soc Nephrol 15 2004 743 753 (Pubitemid 38294805)